Dados B3 › PNVL3 × MGLU3 · Português
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | PNVL3 | MGLU3 | year |
|---|---|---|---|
| ROE | 9.9% | 1.8% | 2025 |
| ROIC | 9.5% | 9.1%! | 2025 |
| ROA | 3.5% | 0.5% | 2025 |
| Gross margin | 32.4% | 29.9% | 2025 |
| EBIT margin | 4.6% | 5.0% | 2025 |
| Net margin | 2.3% | 0.5% | 2025 |
| Net debt/EBITDA | 2.21x | 0.91x | 2025 |
| Current ratio | 1.74x | 1.15x | 2025 |
| Revenue growth (1y) | 11.5% | 1.7% | 2025 |
| Revenue growth (5y CAGR) | 14.4% | 5.8% | 2025 |
| Piotroski F-Score | 7/9 | 4/9 | 2025 |
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | PNVL3 | MGLU3 | year |
|---|---|---|---|
| P/E | 16.98x | 35.59x | 2025 |
| P/B | 1.65x | 0.65x | 2025 |
| EV/EBITDA | 6.55x | 3.18x | 2025 |
| FCF yield | 14.8% | 203.6% | 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-08 14:39 UTC. If this does not match /saude, you are reading a cached copy.
Home · Methodology · Transparency · Audit it